CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma, Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will present at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, NY. This event takes place March 28, 2017 at the New York Academy of Sciences.
Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma will provide an overview on the company and its lead programs at 11:15 a.m. ET.
About Cue Biopharma
Immune Responses, On Cue. Cue Biopharma™ (Cue) is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease. Cue biologics have the potential to be highly effective as monotherapies as well as synergistic with existing checkpoint inhibitors, while reducing collateral toxicities often seen with less selective immunotherapies. Through this platform approach, Cue has developed a promising pipeline with its lead candidate currently approaching the clinic. Headquartered in Kendall Square, Cambridge, MA, Cue is led by a strong, experienced management team and scientific/clinical advisory board with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
For more information, visit www.cuebio.com.